Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Castle Biosciences (Nasdaq: CSTL) will release first quarter 2026 financial results for the period ended March 31, 2026, after market close on Wednesday, May 6, 2026.
Rhea-AI Summary
Castle Biosciences (Nasdaq: CSTL) will release first quarter 2026 financial results for the period ended March 31, 2026, after market close on Wednesday, May 6, 2026. Management will host a live webcast at 4:30 p.m. ET the same day with a brief Q&A following commentary.
Investors can access the live webcast at the provided events link or via the company's Investor Relations webcast page; a replay will be available after the presentation.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CSTL
In the Apr 15 session, CSTL gained 1.03%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- 2025 Revenue
- $344 million
- 2025 full-year revenue cited in DEF 14A
- Test volume growth
- 37%
- DecisionDx-Melanoma and TissueCypher volumes vs 2024
- Cash & securities
- $300 million
- Cash, cash equivalents and marketable securities reported in DEF 14A
- Current price
- $24.37
- Latest pre-news trading price for CSTL
- Daily change
- 3.57%
- Price change in prior 24 hours before this earnings-date news
- Market cap
- $700,745,670
- Equity market capitalization before earnings-date announcement
- Today’s volume
- 189,771 shares
- Trading volume vs 20-day average of 302,815 shares
- Short interest
- 5.27%
- Short interest as a percentage of float
Historical Context
-
Recognition as a 2026 USA TODAY Top Workplaces USA Award recipient.
-
SEER-linked data showing DecisionDx-Melanoma improves five-year survival stratification.
-
Future Oncology study shows i31-SLNB outperforms staging in identifying low-risk patients.
-
Prospective multicenter results confirm low nodal positivity and high three-year RFS.
-
Upcoming SSO 2026 presentation on i31-SLNB identifying patients who may avoid SLNB.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company management will host a webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.
Webcast Details
The live webcast can be accessed here: https://events.q4inc.com/attendee/621816679, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the start time. A replay of the webcast will be available following its conclusion.
There will be a brief Question and Answer session following management commentary.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.
We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/castle-biosciences-to-release-first-quarter-2026-financial-results-and-host-webcast-on-wednesday-may-6-2026-302741021.html
SOURCE Castle Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.